Harel Insurance Investments & Financial Services Ltd. Invests $2.55 Million in Exelixis, Inc. $EXEL

Key Points

• Harel Insurance opened a new Q4 position in Exelixis of 58,128 shares valued at about $2.55 million, joining other institutional adjustments in a stock that is 85.27% institutionally owned.
• Q1 beat but cautious guidance: Exelixis reported $0.87 EPS vs. $0.75 expected and $610.8M revenue, with a strong net margin (~33.7%) and ROE (~36%); FY‑2026 revenue guidance of $2.5–$2.6B is roughly in line with consensus and the stock carries a market consensus rating of "Hold" (avg. target $47).
• Significant insider selling: Insiders have sold 362,849 shares (~$15.9M) over the past 90 days and now own 2.60% of the company, a notable point for investor scrutiny.

Harel Insurance Investments & Financial Services Ltd. purchased a new position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 58,128 shares of the biotechnology company's stock, valued at approximately $2,548,000.

Several other hedge funds have also modified their holdings of the stock. QRG Capital Management Inc. raised its stake in shares of Exelixis by 6.1% in the fourth quarter. QRG Capital Management Inc. now owns 26,278 shares of the biotechnology company's stock valued at $1,152,000 after acquiring an additional 1,516 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of Exelixis in the fourth quarter valued at $279,000. Truist Financial Corp raised its stake in shares of Exelixis by 17.6% in the fourth quarter. Truist Financial Corp now owns 30,476 shares of the biotechnology company's stock valued at $1,336,000 after acquiring an additional 4,553 shares in the last quarter. Seizert Capital Partners LLC raised its stake in shares of Exelixis by 0.7% in the fourth quarter. Seizert Capital Partners LLC now owns 293,943 shares of the biotechnology company's stock valued at $12,884,000 after acquiring an additional 2,081 shares in the last quarter. Finally, Capital Management Corp VA raised its stake in shares of Exelixis by 1.3% in the fourth quarter. Capital Management Corp VA now owns 184,965 shares of the biotechnology company's stock valued at $8,107,000 after acquiring an additional 2,415 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EXEL has been the topic of several analyst reports. Wall Street Zen cut Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 18th. Zacks Research cut Exelixis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, March 5th. Truist Financial upgraded Exelixis to a "strong-buy" rating in a research note on Monday, April 27th. Wells Fargo & Company raised their price target on Exelixis from $30.00 to $35.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 11th. Finally, Royal Bank Of Canada cut their price target on Exelixis from $46.00 to $43.00 and set a "sector perform" rating on the stock in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Exelixis currently has a consensus rating of "Hold" and an average target price of $47.00.

Insider Buying and Selling

In other Exelixis news, EVP Patrick J. Haley sold 67,814 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $43.52, for a total value of $2,951,265.28. Following the completion of the transaction, the executive vice president owned 381,908 shares in the company, valued at $16,620,636.16. This represents a 15.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Bob Oliver sold 30,250 shares of the company's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the transaction, the director owned 21,120 shares of the company's stock, valued at $925,267.20. This represents a 58.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 362,849 shares of company stock valued at $15,917,463 over the last ninety days. Company insiders own 2.60% of the company's stock.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Q1 earnings beat — Exelixis reported $0.87 EPS vs. the $0.75 consensus and revenue of $610.8M vs. ~$607.5M expected; strong net margin (33.7%) and ROE (~36%). This explains much of the intraday strength. Exelixis (EXEL) Tops Q1 Earnings Estimates
• Positive Sentiment: Company release and corporate update highlighted commercial, clinical and pipeline progress — management framed Q1 as advancement toward building next‑generation oncology franchises, supporting investor confidence in the growth story. Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
• Positive Sentiment: Analyst/feature coverage reinforces growth thesis — recent commentary highlights Exelixis as a strong growth stock on fundamentals and style scores, which can support multiple expansion if execution continues. Here's Why Exelixis (EXEL) is a Strong Growth Stock
• Neutral Sentiment: FY‑2026 revenue guidance set at $2.5B–$2.6B — roughly in line with consensus but at the lower end of the range, leaving limited upside in near‑term top‑line expectations; investors will watch guidance detail and cadence. (See company release for guidance context.) Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
• Negative Sentiment: Competitive risk in RCC franchise — coverage ahead of/around earnings questions whether the RCC franchise can sustain share amid intensifying competition; that risk could pressure future growth and is a key watch item for investors. Exelixis earnings on deck: Can RCC franchise weather competition?
• Neutral Sentiment: Earnings roundups and snapshots summarize results and metrics — useful for quick reference but largely reiterate the beats and guidance above. Exelixis: Q1 Earnings Snapshot

Exelixis Price Performance

NASDAQ EXEL opened at $44.42 on Wednesday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $49.62. The company has a market capitalization of $11.28 billion, a PE ratio of 16.04, a P/E/G ratio of 0.99 and a beta of 0.38. The company has a fifty day moving average of $43.32 and a two-hundred day moving average of $42.86.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.75 by $0.12. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The company had revenue of $610.81 million during the quarter, compared to the consensus estimate of $607.51 million. During the same quarter in the prior year, the firm posted $0.55 earnings per share. Exelixis's revenue for the quarter was up 10.0% on a year-over-year basis. On average, research analysts expect that Exelixis, Inc. will post 3.07 earnings per share for the current year.

Exelixis Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis's translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company's most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.